Proscia

Proscia offers a comprehensive digital pathology platform, Concentriq, designed to transform pathology workflows from research and development to clinical diagnostics. It provides purpose-built solutions for life sciences (Concentriq LS) to accelerate biomarker discovery and drug development, and for diagnostics (Concentriq AP and FDA-cleared Concentriq AP-Dx) to digitize labs, improve diagnostic quality, and increase efficiency. The platform integrates advanced digitization, AI, and real-world data to enable faster breakthroughs and more precise patient insights. The platform is utilized by leading academic medical centers, health systems, commercial labs, major CROs, and pharmaceutical companies. Proscia's solutions aim to address challenges like the rising diagnostic burden, pathologist shortages, and the increasing demand for precision medicine by offering intuitive interfaces for interpreting and managing cases, advanced collaboration tools, and AI-powered image analysis. Proscia Aperture, a precision medicine solution, further enhances the platform by turning routine pathology data into actionable, real-time insights, supporting drug development and market access strategies. Proscia's offerings are designed to accelerate the shift to 100% digital diagnosis, empower data science and AI teams, and enable the development and deployment of AI solutions for both therapy development and precision diagnostics. It focuses on improving the pathologist experience, running more efficient labs, and positioning organizations for future growth in the evolving landscape of digital pathology and AI.